Kyowa CDx Tests Approved by Regulators in Japan | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Japanese reagent and medical device firm Kyowa Medex today announced regulators in Japan have approved two companion diagnostics for a drug targeting adult T-cell leukemia-lymphoma (ATL).

The Ministry of Health, Labour, and Welfare approved Kyowa's Poteligeo Test IHC and Poteligeo Test FCM for Kyowa Hakko Kirin's Poteligeo (mogamulizumab) injection, a therapeutic antibody that was also approved by MHLW today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.